Skip to content
Peptigraph home

Semax for ADHD: What the Evidence Shows

What human and animal studies show about Semax for ADHD, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureACTH(4-10) analogUpdated
Strongest evidence
None graded
no study with an outcome for ADHD (PubMed search, 11 Oct 2026)
Human studies
1
PubMed records, our ledger
Animal studies
0
PubMed records, our ledger
Studies we summarised
1
with an outcome for ADHD

Evidence for ADHD

Each row is an outcome related to ADHD from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semax for ADHD: outcomes in published studies
OutcomeResultStudy typeSource
ADHD (hypothesis only)The authors propose, without new data, that semax may help ADHD.ReviewMedical hypotheses 2007, PMID 16996699

PubMed records for Semax and ADHD: 1 human, 0 animal (search counts, not studies we reviewed). Grades follow our .

How strong is it?

Strongest evidence:No graded study for ADHD (PubMed search, 11 Oct 2026)

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

What ADHD is

MedlinePlus calls ADHD a neurodevelopmental disorder, usually first diagnosed in childhood and often lasting into adulthood.[2]

What exists for Semax and ADHD

The ADHD PubMed query for Semax (run 2026-10-02) found 1 human-tagged record, 0 animal records, 0 randomized trials and 1 in all.

Calculated from human 1; animal 0; rct 0; all 1. Formula: Counts copied from the semax ledger row of the adhd goal in goals.json; no arithmetic.

That single record is a hypothesis paper, not a trial: its authors propose that Semax may have good therapeutic potential in ADHD because of its links to dopamine and BDNF.[1]

The paper's rationale is that a number of patients with ADHD either fail to respond to psychostimulants or experience side effects that preclude their use.[1]

Attention-related data that do exist

The paper says Semax stimulates memory and attention in rodents and humans after intranasal use, citing earlier work rather than an ADHD trial.[1]

An fMRI study in 11 men and 13 women found a bigger rostral default mode network subcomponent after 1% intranasal Semax than placebo; it measured brain scans, not attention or behaviour.[3]

A rat chronic-stress study found that chronic Semax treatment reversed or attenuated anhedonia and a decrease in hippocampal BDNF.[4]

Other peptides people research for ADHD

All peptides for ADHD, compared

Common questions

Does Semax help with ADHD?

None of the studies we summarised for Semax (PubMed search, 11 Oct 2026) measured an outcome for ADHD. Treat claims that it helps with ADHD as unproven.

Is Semax approved for ADHD?

No. Semax is not FDA approved for any use, including ADHD.

What is the best peptide for ADHD?

There is no single answer. Our ADHD overview compares each candidate by evidence grade and legal status rather than by popularity.

Does Semax help ADHD?

The only ADHD-specific record is a hypothesis paper proposing that Semax may have good therapeutic potential in ADHD. The other data are healthy-volunteer imaging and rat studies.[1]

Is Semax a stimulant?

The hypothesis paper describes Semax as an analogue of ACTH fragment 4-10 that is completely devoid of hormonal activity.[1]

More on Semax

Sources

  1. 1Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.Medical hypotheses · 2007PMID 16996699Accessed 2 Oct 2026
  2. 2Official web pageOfficial web page · web page
  3. 3Effects of Semax on the Default Mode Network of the Brain.Bulletin of experimental biology and medicine · 2018PMID 30225715Accessed 2 Oct 2026
  4. 4Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.European journal of pharmacology · 2024PMID 39442746Accessed 2 Oct 2026

Found an error? Report a correction.